Results 141 to 150 of about 12,926,992 (276)

Real‐World Effectiveness and Safety of Secukinumab in Giant Cell Arteritis: An Italian Multicenter Cohort Study

open access: yesArthritis Care &Research, EarlyView.
Objective The objective of this study was to evaluate the real‐world effectiveness and safety of secukinumab in patients with giant cell arteritis (GCA). Methods This multicenter retrospective study included patients with GCA who received secukinumab at 14 Italian centers with at least six months of follow‐up.
Luca Iorio   +28 more
wiley   +1 more source

Generative Artificial Intelligence Utilization and Perspectives Among Reproductive‐Age Women With Systemic Autoimmune and Rheumatic Diseases

open access: yesArthritis Care &Research, EarlyView.
Objective Reproductive‐age women with systemic autoimmune and rheumatic diseases (SARDs) have unique information needs related to their SARDs and reproductive health. We sought to understand their use of and receptivity to current and hypothetical generative artificial intelligence (AI) tools for health information‐seeking. Methods We conducted a cross‐
Mariam Arif   +5 more
wiley   +1 more source

Real‐World Safety of Concomitant Colchicine and Statin Therapy

open access: yesArthritis Care &Research, EarlyView.
Objective This study aimed to evaluate the risk of clinically meaningful muscle‐ and liver‐related outcomes associated with concomitant colchicine–statin therapy in a real‐world setting, and to determine whether concomitant therapy increases the incidence of toxicity compared with either agent alone.
Roni Meidan   +5 more
wiley   +1 more source

Patients improve, patterns persist: longitudinal stability of RA joint involvement patterns

open access: yesArthritis Care &Research, Accepted Article.
Objective Rheumatoid arthritis is a heterogeneous disease. Data‐driven approaches, from synovial histology to joint involvement patterns (JIPs), have sought to define clinically meaningful subgroups. Whether these subgroups represent stable phenotypes or transient disease states remains unclear.
Tjardo Maarseveen   +24 more
wiley   +1 more source

Development of Patient‐Reported Outcome Measures for Early Systemic Sclerosis Across Disease Subtypes

open access: yesArthritis Care &Research, Accepted Article.
Objective Existing patient‐reported outcome (PRO) measures for systemic sclerosis (SSc) have important limitations, including inadequate coverage of early disease and limited inclusion of diffuse cutaneous (dcSSc) and limited cutaneous (lcSSc) subtypes.
George J. Greene   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy